These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 185524)

  • 41. Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus.
    Herberman RB; Aoki T; Nunn M; Lavrin DH; Soares N; Gazdar A; Holden H; Chang KS
    J Natl Cancer Inst; 1974 Oct; 53(4):1103-11. PubMed ID: 4139276
    [No Abstract]   [Full Text] [Related]  

  • 42. Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas.
    Grant JP; Bigner DD; Fischinger PJ; Bolognesi DP
    Proc Natl Acad Sci U S A; 1974 Dec; 71(12):5037-41. PubMed ID: 4373739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunological aspects of human leukaemia.
    Viza D
    Ser Haematol; 1972; 5(5):87-108. PubMed ID: 4133766
    [No Abstract]   [Full Text] [Related]  

  • 44. Expression of type C viral glycoproteins on P815 cells: higher expression of Mr 70,000 glycoprotein-containing glycoprotein on immunogenic variants.
    Jacquemin PC
    Cancer Res; 1982 Sep; 42(9):3828-36. PubMed ID: 6286113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-leukemogenic variants of Rauscher leukemia virus obtained in long-term cultures at supra-optimal temperature.
    Barski G; Barbieri D; Youn JK; Hue G
    Int J Cancer; 1973 Jul; 12(1):55-65. PubMed ID: 4597863
    [No Abstract]   [Full Text] [Related]  

  • 46. Immune responses to virus induced experimental leukemia and to human leukemia.
    Herberman RB
    Johns Hopkins Med J Suppl; 1974; 3():3-14. PubMed ID: 4371287
    [No Abstract]   [Full Text] [Related]  

  • 47. Investigation of immunizing properties as well as interferogenicity of some murine leukemia viruses.
    Mazurenko NP; Revazova ES
    Arch Geschwulstforsch; 1970; 35(4):308-14. PubMed ID: 4325787
    [No Abstract]   [Full Text] [Related]  

  • 48. [Study of group- and type-specific antigens in the process of development of viral murine leukemias].
    Gurtsevich VE; Mazurenko NP
    Vopr Onkol; 1973; 19(1):66-70. PubMed ID: 4121908
    [No Abstract]   [Full Text] [Related]  

  • 49. In vitro cytotoxicity by a nonthymus-processed lymphocyte population with specificity for a virally determined tumor cell surface antigen.
    Lamon EW; Skurzak HM; Klein E; Wigzell H
    J Exp Med; 1972 Nov; 136(5):1072-9. PubMed ID: 4117188
    [No Abstract]   [Full Text] [Related]  

  • 50. Macrophage-mediated in vitro sensitization of T-lymphocytes. I; Detection of murine leukemia virus-associated antigens.
    Treves AJ; Feldman M; Kaplan HS
    J Natl Cancer Inst; 1977 May; 58(5):1527-9. PubMed ID: 192905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of various extraction procedures for the solubilization of murine transplantation antigens.
    Sagi S; Young JM; Gyenes L
    Tissue Antigens; 1973; 3(3):179-88. PubMed ID: 4771173
    [No Abstract]   [Full Text] [Related]  

  • 52. Induction of antinuclear antibodies in (CxB6) F1 mice inoculated with Graffi and Rauscher leukemogenic viruses.
    Cannat A; Varet B
    Proc Soc Exp Biol Med; 1972 Dec; 141(3):1077-80. PubMed ID: 4345703
    [No Abstract]   [Full Text] [Related]  

  • 53. Evidence for non-exposed H-2 antigens in immunoresistant murine tumour.
    Friberg S; Lilliehöök B
    Nat New Biol; 1973 Jan; 241(108):112-4. PubMed ID: 4512450
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunology of virus-induced tumours.
    Sjögren HO
    Mod Trends Med Virol; 1967; 1(0):207-22. PubMed ID: 4366129
    [No Abstract]   [Full Text] [Related]  

  • 55. Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.
    Green WR; Nowinski RC; Henney CS
    J Immunol; 1980 Aug; 125(2):647-55. PubMed ID: 6156211
    [No Abstract]   [Full Text] [Related]  

  • 56. Dynamic aspects of the interaction between antibodies and complement at the cell surface.
    Sundqvist KG; Svehag SE; Thorstensson RT
    Scand J Immunol; 1974; 3(3):237-50. PubMed ID: 4211939
    [No Abstract]   [Full Text] [Related]  

  • 57. Association of HL-A antigens and beta 2-microglobulin: concepts and questions.
    Poulik MD; Ferrone S; Pellegrino MA; Sevier DE; Oh SK; Reisfeld RA
    Transplant Rev; 1974; 21(0):106-25. PubMed ID: 4139784
    [No Abstract]   [Full Text] [Related]  

  • 58. The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes.
    Iezzi G; Rivolta L; Ronchetti A; Martin-Fontecha A; Rosato A; Protti MP; Sabbadini MG; Bellone M
    Cancer Res; 1997 Jul; 57(13):2564-8. PubMed ID: 9205054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship of membrane antigens on 141 (NZB) and EL4 (C57BL) lymphoma cells as demonstrated by antibody-induced resistance to complement-mediated cytotoxicity.
    Ran M; Yaakubowicz M; Talal N; Witz IP
    Eur J Immunol; 1978 Jun; 8(6):423-8. PubMed ID: 78855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus.
    Collins JJ; Roloson G; Haagensen DE; Fischinger PJ; Wells SA; Holder W; Bolognesi DP
    J Natl Cancer Inst; 1978 Jan; 60(1):141-52. PubMed ID: 203701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.